Free Trial

Pharvaris (PHVS) Competitors

Pharvaris logo
$19.83 +1.33 (+7.19%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.96 +0.14 (+0.68%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PHVS vs. SWTX, RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, and KYMR

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

Pharvaris vs. Its Competitors

Pharvaris (NASDAQ:PHVS) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Pharvaris currently has a consensus target price of $36.20, indicating a potential upside of 82.55%. SpringWorks Therapeutics has a consensus target price of $52.57, indicating a potential upside of 11.88%. Given Pharvaris' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pharvaris is more favorable than SpringWorks Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
SpringWorks Therapeutics
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13

Pharvaris has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$145.24M-$3.01-6.59
SpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78

Pharvaris has a beta of -2.82, indicating that its stock price is 382% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Pharvaris has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -115.60%. SpringWorks Therapeutics' return on equity of -51.10% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -54.02% -50.36%
SpringWorks Therapeutics -115.60%-51.10%-43.80%

In the previous week, Pharvaris had 2 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 4 mentions for Pharvaris and 2 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.54 beat Pharvaris' score of 0.61 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SpringWorks Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Pharvaris beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$967.37M$2.96B$5.55B$9.03B
Dividend YieldN/A2.43%5.25%4.04%
P/E Ratio-6.5921.1127.2320.14
Price / SalesN/A181.16372.0580.52
Price / CashN/A42.7337.5058.41
Price / Book3.587.748.075.60
Net Income-$145.24M-$54.96M$3.16B$248.43M
7 Day Performance5.70%9.10%4.70%5.47%
1 Month Performance16.30%5.73%4.50%7.87%
1 Year Performance8.72%2.79%30.79%18.75%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHVS
Pharvaris
1.5407 of 5 stars
$19.83
+7.2%
$36.20
+82.6%
+11.9%$967.37MN/A-6.5930Gap Up
SWTX
SpringWorks Therapeutics
1.713 of 5 stars
$46.99
+0.0%
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
RNA
Avidity Biosciences
2.1577 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-26.0%$3.50B$10.90M-9.47190Analyst Forecast
RARE
Ultragenyx Pharmaceutical
4.0267 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-26.9%$3.45B$560.23M-6.181,294Trending News
Analyst Forecast
Gap Down
PTGX
Protagonist Therapeutics
2.5218 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+51.9%$3.45B$434.43M73.69120Positive News
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.45B$134.35M0.00600News Coverage
SRRK
Scholar Rock
3.3631 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+360.9%$3.40B$33.19M-14.00140Insider Trade
MLTX
MoonLake Immunotherapeutics
2.0005 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+8.7%$3.04BN/A-20.522Positive News
MTSR
Metsera
N/A$28.45
-0.5%
$55.00
+93.3%
N/A$3.00BN/A0.0081
VKTX
Viking Therapeutics
3.8936 of 5 stars
$26.50
-0.1%
$87.15
+228.9%
-46.0%$2.98BN/A-23.0420
KYMR
Kymera Therapeutics
3.1944 of 5 stars
$43.64
-1.1%
$59.61
+36.6%
+24.7%$2.87B$47.07M-14.08170Analyst Revision

Related Companies and Tools


This page (NASDAQ:PHVS) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners